本帖最后由 老马 于 2013-3-13 13:43 编辑
- [; j1 i7 B9 I: M' }
( ?4 H# [- E8 i4 M- ]2 I" Y; b健择（吉西他滨）+顺铂+阿瓦斯汀: ?/ \# X. c M6 O/ C9 U% N& z9 ?& }
Gemzar +Cisplatin + Avastin" t+ j$ C4 n7 [6 [9 E- |- A( y
http://annonc.oxfordjournals.org/content/21/9/1804.full
6 {" H/ x0 c+ k* F. sOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
3 P) H0 Y. N9 f; y- i, sPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
# y- ~' U( v/ z+ SResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
# p$ W& Y P8 S V4 G+ e2 B
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 328)
^+ l; \5 G9 L6 _0 p' V华为网盘附件：
5 S; Z ^" u' [( \【华为网盘】ava.JPG
" C3 y! }/ l( b: w |
显身卡
